COMP <GO>
TGTX vs LLY // EV/EBITDA & P/E VALUATION
TG Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: TGTX 7
— LLY 8
▲ EV/EBITDA & P/E VALUATION LEADER: LLY
LAST: $61.18 (+5.34%) • MKT CAP: $8.89B
valuation
73.3x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TGTX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TGTX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.70% | 83.64% | +0.06 | TGTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.00% | 32.36% | -20.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 73.3x | 36.4x | +36.88 | LLY | /valuation <GO> |
| Free Cash Flow Yield | -0.28% | 2.30% | -2.58 | LLY | /fcf-yield <GO> |
| Operating Margin | 20.00% | 40.21% | -20.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 31.90% | +36.10 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 87.30% | 45.51% | +41.79 | TGTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.92 | 9.29 | +3.63 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | TGTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.7 | 77.9 | -8.17 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.51 | +0.36 | TGTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.7x | 26.3x | -9.55 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.89B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TGTX REV | LLY REV | TGTX GROSS % | LLY GROSS % | TGTX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $616.3M | $65.18B | 83.7% | 83.0% | -$25.0M | $16.81B |
| FY 2024 | $329.0M | $45.04B | 88.3% | 81.3% | -$40.6M | $8.82B |
| FY 2023 | $233.7M | $34.12B | 44.0% | 79.3% | -$41.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TGTX // BETA 0.87
LLY // BETA 0.51